XML 66 R30.htm IDEA: XBRL DOCUMENT

Subsequent events (Notes)	6 Months Ended
Subsequent events (Notes)	Dec. 31, 2015
Subsequent Event [Line Items]
Subsequent Events [Text Block]	SUBSEQUENT EVENTS Matawan Pharmaceuticals, LLC portfolio On January 22, 2016, we acquired a portfolio of generic dosage forms and strengths of Retin-A^®(tretinoin), which is a topical prescription acne treatment, from Matawan Pharmaceuticals, LLC, for $415.0 million in cash, which was funded primarily by borrowings under our 2014 Revolver and 2015 Revolver. We were the authorized generic distributor of these products from 2005 to 2013. The acquisition complements our Rx portfolio, furthering our "extended topicals" strategy. A preliminary valuation and purchase price allocation will be completed for the acquisition during the first quarter of 2016. We expect the majority of the purchase price to be allocated to the acquired definite-lived intangible assets.